6 not yet recruiting, 4 recruiting, 1 active not recruiting, 1 unknown. 7 Phase 2, 6 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Not yet recruiting 5, Recruiting 1, Unknown 1 |
| Phase 3 | 6 | Recruiting 3, Not yet recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Not yet recruiting 2 |
Follow HB1801: new trials by email Literature Review of HB1801 trials Research Report on HB1801
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer HB1801, Docetaxel (Taxotere®) - HER2-Negative Advanced Breast Cancer | Phase 3 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 430 | 2026-08-31 | 2026-09-04 |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer KN026, HB1801, Trastuzumab - Resectable HER2-positive Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 1800 | 2026-03-06 | 2026-04-08 |
| HB1801 Combined Treatment of HER2-positive Breast Cancer HB1801, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 80 | 2025-09-15 | 2025-08-12 |
| A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer HB1801, Taxotere® - Advanced Breast Cancer | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 60 | 2025-08-15 | 2025-07-24 |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer KN026, HB1801, Pertuzumab - Early or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Shanghai JMT-Bio Inc. | 520 | 2024-12-16 | 2026-07-07 |
| Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. SYHA1813, SG001, HB1801 - Unresectable Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Runshi Pharmaceutical Technology Co., Ltd | 380 | 2024-11-13 | 2024-11-12 |
| Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer JMT101, docetaxel, HB1801 - Squamous Cell Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 534 | 2024-05-01 | 2024-03-20 |
| A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer Docetaxel for injection (Albumin-bound), Taxotere (docetaxel) - Gastric Cancer | Phase 3 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 630 | 2024-02-27 | 2024-11-14 |
| A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. Docetaxel for Injection (Albumin-bound), SG001, Cisplatin for injection - Locally Advanced Unresectable Esophageal Squamous Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 129 | 2023-12-01 | 2023-11-18 |
| Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. Recombinant Humanized Bispecific antibody against HER2，KN026, HB1801, Pertuzumab - First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 880 | 2023-07-23 | 2025-05-30 |
| A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) HB1801, Taxotere - Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 80 | 2023-06-27 | 2023-11-07 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (6) · Shanghai JMT-Bio Inc. (4) · Fudan University (1) · Shanghai Runshi Pharmaceutical Technology Co., Ltd (1)
China (7)
Li Zhang, M.D. (1) · Ruihua Xu, Doctor (1) · Ying Cheng (1) · Zhimin Shao, Professor (1)